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Abstract
BPR0L075 [6-methoxy-3-(39,49,59-trimethoxy-benzoyl)-1H-indole] is a novel anti-microtubule drug with anti-tumor and anti-
angiogenic activities in vitro and in vivo. Securin is required for genome stability, and is expressed abundantly in most
cancer cells, promoting cell proliferation and tumorigenesis. In this study, we found that BPR0L075 efficiently induced cell
death of HCT116 human colorectal cancer cells that have higher expression levels of securin. The cytotoxicity of BPR0L075
was attenuated in isogenic securin-null HCT116 cells. BPR0L075 induced DNA damage response, G2/M arrest, and activation
of the spindle assembly checkpoint in HCT116 cells. Interestingly, BPR0L075 induced phosphorylation of securin. BPR0L075
withdrawal resulted in degradation of securin, mitotic exit, and mitotic catastrophe, which were attenuated in securin-null
cells. Inhibition of cdc2 decreased securin phosphorylation, G2/M arrest and cell death induced by BPR0L075. Moreover,
BPR0L075 caused cell death through a caspase-independent mechanism and activation of JNK and p38 MAPK pathways.
These findings provided evidence for the first time that BPR0L075 treatment is beneficial for the treatment of human
colorectal tumors with higher levels of securin. Thus, we suggest that the expression levels of securin may be a predictive
factor for application in anti-cancer therapy with BPR0L075 in human cancer cells.
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Introduction
Microtubules are a component of the cytoskeleton and are
composed of a-tubulin and b-tubulin heterdimers [1]. Microtu-
bules are especially important in mitosis and cell division, and this
has meant that microtubules have become a target for anticancer
drugs [2,3]. According to different tubulin-binding sites, anti-
microtubule drugs are classified into three classes: the paclitaxel
site, the vinca alkaloid site, and the colchicines domain. Anti-
microtubule drugs could induce either microtubule stabilization,
such as seen with paclitaxel, or destabilization, as seen with
vinblastine and colchicine [4]. BPR0L075 [6-methoxy-3-(39,49,59-
trimethoxy-benzoyl)-1H- indole], a Combretastatin A-4 (CA-4)
analog, which is derived from the South African tree Combretum
caffrum, is a novel synthetic anti-microtubule drug that inhibits
tubulin polymerization by binding to the colchicine domain [5],
and was approved by the U.S. FDA for phase 1 clinical trials in
2010. Recent studies have reported that BPR0L075 exerts not
only anti-mitotic and anti-tumor activities but also anti-angiogenic
activity in vitro and in vivo [6,7].
Mitotic catastrophe is a form of cell death that results from
abnormal mitosis [8]. It can be triggered by drugs influencing
microtubule stability, various anticancer drugs, ionizing radiation
and mitotic failure induced by cell cycle checkpoint defect [8,9].
Furthermore, mitotic catastrophe can be caspase-dependent or –
independent [10]. Biochemical features of mitotic catastrophe are
prolonged spindle assembly checkpoint (SAC) signaling, aberrant
levels of cyclin B1, and signaling via Cdk1 [11]. Cell death caused
by mitotic catastrophe might occur during or after mitosis [12].
Anti-microtubule drugs, such as docetaxel and Combretastatin-A4
prodrug (CA4P), induce cancer cell death through mitotic
catastrophe [13,14]. These findings suggest a potential role of
BPR0L075 in inducing mitotic catastrophe in human cancer cells.
Whether or not mitotic catastrophe induced by BPR0L075
treatment contributes to cancer cell death is worthy of investiga-
tion.
Securin, also known as the pituitary tumor transforming gene
(PTTG1), was first isolated from rat pituitary tumor cells [15].
Securin is a multi-functional protein that regulates sister chromatin
segregation in mitosis [16], DNA repair [17], gene transcription
[18], metabolism and organ development [19–21]. In normal
tissue, securin expression is high in the testis and low in the
thymus, colon and small intestine [22]. In contrast, securin has
been identified as an oncogene and a marker of invasiveness due to
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6its overexpression in a variety of tumors [23], and has been found
to regulate tumor cell proliferation and tumorigenesis [24,25]. In
our previous studies, anticancer agents such as oxaliplatin and
fisetin were shown to induce cancer cell death through down-
regulation of securin expression [26–28]. BPR0L075 possesses
anti-tumor and anti-angiogeneic activities by inhibiting the
function of microtubules, especially at the metaphase to anaphase
transition in mitosis [6,7]. Securin is also a protein that is involved
in control of the metaphase-anaphase transition and anaphase
onset. However, the effectiveness of BPR0L075 in patients with
cancers highly-expressing securin is still unknown.
In this study, we investigated the role of securin in interfering
with sensitivity to BPR0L075 in human cancer cells and showed
for the first time that phosphorylation and destabilization of
securin enhances sensitivity to the microtubule de-stabilizing
compound BPR0L075 in HCT116 human colorectal cancer cells.
We further elucidated the molecular mechanisms of the cell death
induced by BPR0L075 in HCT116 cells. Our findings indicate
that securin appears to be a suitable clinical target for BPR0L075
treatment.
Results
The anticancer effects of BPR0L075 were correlated with
the expression levels of securin in human cancer cells
To investigate the role of securin in the anticancer effects of
BPR0L075, several human cancer cells with different securin
expression levels, including lung cancer cells (A549), human breast
cells (MCF-7 and MDA-MB-231), melanoma (MDA-MB-435) and
colorectal cancer cells (HCT116), were used (Fig. 1A). After
treatment with BPR0L075 for 24 h, their cell viability was
efficiently inhibited. Among them, HCT116 cells with the highest
expression level of securin exhibited the greatest sensitivity to
BPR0L075 (Fig. 1B). To ascertain the role of securin in the
Figure 1. BPR0L075 induced cytotoxicity in various human cancer cell lines with different expression levels of endogenous securin.
(A) The levels of securin in A549, MCF-7, MDA-MB-231, MDA-MB-435 and HCT116 cells were characterized by Western blot analysis. (B) Cells were
treated with the indicated concentrations of BPR0L075 for 24 h. The cell viability was examined by MTT assay. (C) The cell viability of securin-wild-
type and -null HCT116 cells was measured by MTT assay. p,0.01(**) indicates a significant difference between BPR0L075-treated and untreated
samples. p,0.01(##) indicates a significant difference between securin-wild-type and -null HCT116 cells.
doi:10.1371/journal.pone.0036006.g001
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BPR0L075 and the cell viability was then examined by MTT
assay. As expected, the cytotoxicity of BPR0L075 was reduced in
securin-null HCT116 cells (Fig. 1C), indicating that securin
expression enhanced the anticancer effects of BPR0L075.
Loss of securin expression attenuated the cytotoxicity of
BPR0L075 through decreases of G2/M arrest and
apoptosis in HCT116 colorectal cancer cells
To further characterize the role of securin in BPR0L075-
induced cytotoxicity, cell cycle progression and cell death were
analyzed by flow cytometry. BPR0L075 was found to induce G2/
M arrest (Fig. 2A) and apoptosis (Fig. 2B) in HCT116 cells, which
was attenuated in securin-null cells. Interestingly, colchicine-
induced G2/M arrest was also reduced in securin-null HCT116
cells (Fig. 2A), whereas cisplatin induced similar fractions of
apoptosis in securin-wild-type and -null HCT116 cells (Fig. 2B).
These results suggested that securin is specifically required for the
anticancer effects of microtubule-targeting drugs.
Securin enhanced BPR0L075-induced DNA damage
response and spindle assembly checkpoint in HCT116
cells
Anticancer agents can cause DNA damage of cancer cells and
consequently activate cell cycle checkpoints, leading to cell cycle
arrest, and allow the cells to repair before entering mitosis. If the
cells fail to repair, cell death through apoptosis will ensue [29,30].
c-H2AX is regarded as a checkpoint maintenance factor, and its
dephosphorylation enables resumption of the cell cycle after DNA
damage is repaired [31]. To investigate whether BPR0L075
induced a DNA damage response in HCT116 cells, the protein
levels of c-H2AX after BPR0L075 treatment were analyzed using
western blot. BPR0L075 induced c-H2AX expression in both
securin-wild-type and -null HCT116 cells (Fig. 3A). In response to
DNA damage, two distinct kinase signaling cascades, the ATM/
Chk2 and ATR/Chk1 pathways, are activated [32]. The levels of
phosphorylation of Chk1 and Chk2 were elevated by BPR0L075
treatment in both securin-wild-type and -null HCT116 cells.
Moreover, the activation of Chk1 and Chk2 was higher in the
securin-wild-type cells than in the securin-null HCT116 cells after
BPR0L075 treatment (Fig. 3A).
Treatment of cells with microtubule inhibitors results in
activation of the mitotic spindle assembly checkpoint (SAC),
leading to mitotic arrest before anaphase [33]. Besides, activation
of SAC also inhibits the anaphase-promoting complex/cyclosome
(APC/C), leading to the stabilization of securin and cyclin B1 [34].
To elucidate whether BPR0L075 activated SAC, HCT116 cells
were treated with BPR0L075 and the expression levels of SAC-
related mitotic markers such as phospho-Histone H3 (Ser10),
cyclin B1, and phospho-cdc2 (Thr161) were examined. These
mitotic markers were induced in both securin-wild-type and -null
HCT116 cells (Fig. 3B). However, the extent of SAC activation
was lower in securin-null cells (Fig. 3B). In addition, the expression
of phospho-securin was induced by more than 10 nM BPR0L075
in wild-type HCT116 cells (Fig. 3B), which was correlated with the
increase of G2/M arrest (Fig. 2A). Securin is enriched in G2/M
phase and degraded after mitotic exit [35]. Consistently, the
securin expression was reduced by 10 nM BPR0L075, in which
G2/M arrest was not occurred (Fig. 2A and 3B). Therefore,
BPR0L075 induced DNA damage and SAC, which can be
enhanced in the presence of securin in HCT116 cells.
BPR0L075 induced securin phosphorylation and affected
the stability of mitotic regulatory molecules in HCT116
cells
It was noted that securin tended to be significantly band-shifted
after BPR0L075 treatment in HCT116 cells (Fig. 3B). To explore
whether the band-shift of securin was a result of its phosphory-
lation, BPR0L075-treated protein extracts were incubated with
Figure 2. Effects of BPR0L075 on cell cycle progression and apoptosis in securin-wild-type and -null HCT116 cells. Cells were treated
with 5 to 80 nM BPR0L075 for 24 h. (A) The cell cycle distribution was analyzed by flow cytometry. The percentages of G2/M cells were quantified. (B)
Cell apoptosis was determined by Annexin-V/PI double staining. Apoptotic cells were quantified by both Annexin-V positive and Annexin-V/PI double
positive cells. p,0.01(**) indicates a significant difference compared to untreated samples. p,0.01(##) indicates a significant difference between
securin-wild-type and -null HCT116 cells.
doi:10.1371/journal.pone.0036006.g002
Figure 3. Comparison of the effects of BPR0L075 on DNA
damage response and spindle assembly checkpoint activation
in securin-wild-type and -null HCT116 cells. Cells were treated
with 10,80 nM BPR0L075 for 24 h. (A) The levels of c-H2AX, phospho-
chk1, phospho-chk2, total chk1 and chk2 were analyzed by Western
blot in BPR0L075-treated securin-wild-type and -null HCT116 cells. (B)
The levels of securin, phospho-H3 (Ser10), cyclin B1, phospho-cdc2
(Thr161) and total cdc2 were ascertained by Western blot analysis.
doi:10.1371/journal.pone.0036006.g003
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band-shift of securin was decreased by AP (Fig. 4A), suggesting
that BPR0L075 induced securin phosphorylation. To further
confirm this phenomenon, several anti-microtubule drugs, includ-
ing colchicine, paclitaxel, and vinblastine, were used to induce
mitotic arrest. As shown in Fig. 4B, treatment with anti-
microtubule drugs also resulted in band-shift of securin. Intrigu-
ingly, an intermediate migrating band (as indicated by asterisk) of
securin was observed in BPR0L075-treated cells (Fig. 4B). Since
six phosphorylation sites on securin have been identified [36], this
band might represent a transient hypophosphorylated form of
securin. Indeed, an in vitro securin phosphorylation assay shows
two slower migration bands of phosphorylated securin [37].
The stability of securin depends on its phosphorylation state.
Hyperphosphorylated forms are rapidly destroyed via the Skp1/
Cul1/F-box protein complex (SCF) E3 ubiquitin ligase [38]. To
examine whether BPR0L075-induced securin phosphorylation
affected its protein stability, cells were treated with 20 nM
BPR0L075 for 12 h and then recovered in medium containing
either the proteasome inhibitor MG132 or the protein synthesis
inhibitor cycloheximide (CHX) for 2–24 h. It was found that, after
BPR0L075 withdrawal, the phosphorylated form of securin was
rapidly degraded, and addition of MG132 blocked its degradation
(Fig. 4C). In contrast, the hypophosphorylated form of securin was
increased during cell recovery, which could be blocked by CHX
treatment (Fig. 4D), suggesting that securin is re-synthesized after
recovery from BPR0L075. The degradation rate of securin was
similar to that of other mitotic regulatory molecules including
cyclin B1 and phospho-histone H3 in wild-type HCT116 cells
(Fig. 4C and 4D). Interestingly, the accumulation of phospho-
histone H3 was higher in MG132-treated securin-null cells
(Fig. 4C), and the decreases of cyclin B1 and phospho-histone
H3 were lower in CHX-treated securin-null cells (Fig. 4D). These
results showed that BPR0L075 treatment induced instability of
mitotic regulatory molecules in the presence of securin.
BPR0L075 induced mitotic catastrophe in HCT116 cells
Mitotic catastrophe is a form of cell death during or after
abnormal mitosis [8]. Our results suggested that BPR0L075
induced phosphorylation of securin, which may destabilize mitotic
regulatory molecules and consequently promote mitotic catastro-
phe in HCT116 cells. To address this possibility, securin-wild-type
and -null HCT116 cells treated with 20 nM BPR0L075 for 12 h
were recovered in culture medium for 12–96 h, and cell cycle
progression and apoptosis were then analyzed using flow
cytometry. The results indicated that, after BPR0L075 removal,
Figure 4. Effects of BPR0L075 on phosphorylation and instability of securin in HCT116 cells. (A) Cells were treated with 20 nM BPR0L075
for 24 h. Cell lysates were subjected to alkaline phosphatase assay and the levels of securin were determined by Western blot. (B) Cells were treated
with 0 to 80 nM BPR0L075, colchicine, paclitaxel and vinblastine for 24 h. (C and D) Cells were treated with or without MG132/cycloheximide for 2 to
24 h after 24 h of BPR0L075 treatment. The cell lysates were subjected to Western blot analysis using antibodies specific for cyclin B1, phospho-H3
(Ser10) and securin.
doi:10.1371/journal.pone.0036006.g004
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resumed in securin-wild-type and -null HCT116 cells (Fig. 5A).
However, the decreases of the G2/M fraction in securin-wild-type
cells were more significant than those in the securin-null cells,
which was reflected by the increases in G0/G1 and S phase cells in
wild-type cells (Fig. 5A). In addition, the increases in the sub-G1
fraction were also higher in securin-wild-type cells (Fig. 5A),
suggesting that securin expression promoted mitotic catastrophe in
HCT116 cells. Furthermore, cell apoptosis after BPR0L075
withdrawal was analyzed by annexin V/PI double staining.
Consistently, more cell apoptosis in securin-wild-type cells was
induced after cell recovery for 24 h (Fig. 5B and 5C).
BPR0L075 induced phosphorylation of securin, G2/M
arrest and cytotoxicity through a cdc2 (cdk1)-dependent
pathway
Securin is phosphorylated by cdc2 (cdk1) [39]. To investigate
whether cdc2 signaling is responsible for the BPR0L075-induced
phosphorylation of securin, the effects of cdc2, CDK and cdc25
specific inhibitors (alsterpaullone, purvalanol or NSC 663284,
respectively) on BPR0L075-induced phosphorylation of securin
were monitored. The phosphorylation of securin was partially
decreased by cdc2/CDK inhibitors (Fig. 6A). In addition, we also
showed that inhibition of cdc2 or CDK reduced BPR0L075-
induced G2/M arrest and cytotoxicity in securin-wild-type
HCT116 cells (Fig. 6B and 6C). These results suggest that in
response to BPR0L075 treatment, cdc2 phosphorylated securin,
leading to higher G2/M arrest and thus facilitating the cytotoxicity
of BPR0L075 in HCT116 cells.
BPR0L075-induced cell death through activation of the
JNK and p38 MAPK pathways and a caspase-
independent mechanism in HCT116 cells
In response to external stresses or damage, cells usually activate
the JNK or p38 MAPK pathways, leading to cell death [40], or the
ERK pathway for survival [41]. It has been reported that
activation of p38 MAPK or inhibition of ERK is involved in the
apoptosis induced by the anti-microtubule drug nocodazole alone
or combination with paclitaxel [42,43]. To address the role of
MAPK pathways in BPR0L075-induced cell death in securin-
wild-type HCT116 cells, the activations of p38 MAPK, JNK and
ERK were analyzed by western blot. The p38 MAPK, JNK and
ERK pathways were activated by BPR0L075 (Fig. 7A). Specific
inhibitors of p38 MAPK, JNK and ERK (SB2021900, SP600125
and U0126, respectively) blocked the BPR0L075-induced activa-
tion (Fig. 7B and 7C). However, inhibition of the p38 MAPK,
JNK and ERK pathways did not affect BPR0L075-induced
phosphorylation of securin (Fig. 7B and 7C). In addition, only
SP600125 inhibited BPR0L075-induced phospho-Histone H3
(Fig. 7B).
We further analyzed the effects of MAPK inhibitors on
BPR0L075-induced cytotoxicity by MTT assay. Treatment with
SB202190, SP600125 or U0126 alone did not affect cell survival in
HCT116 cells (Fig. 7D). Moreover, SB202190 and SP600125
were able to rescue cells from BPR0L075-induced cytotoxicity
(Fig. 7D). These results indicate that activation of the p38 MAPK
and JNK pathways are required for BPR0L075-induced cell death
in HCT116 cells. To further investigate whether caspase
activation is involved in BPR0L075-induced cell death, the cell
viability of cells pretreated with pan caspase inhibitor, z-VAD-fmk,
combined with BPR0L075 treatment was analyzed by MTT
assay. We found that inhibition of caspase did not affect the cell
viability after BPR0L075 treatment (Fig. 7E). Moreover,
BPR0L075-induced activation of the p38 MAPK and ERK
pathways, as well as phosphorylation of securin and Histone H3,
were not affected. These results imply that BPR0L075 induced cell
death through a caspase-independent pathway in HCT116 cells.
Discussion
Securin, an oncogene, is overexpressed in various cancer cells
and is responsible for promoting cell proliferation and tumorigen-
esis [24,25]. Previously, it has been reported that securin levels are
down-regulated in HCT116 cell death induced by chemothera-
peutic drugs [26,44], suggesting that it might be a target for cancer
therapy. In this study, we found that the cytotoxicity of the anti-
microtubule drug BPR0L075 was positively correlated with the
expression levels of securin in various cancer cells. Securin was
phosphorylated by treatment with BPR0L075 as well as other anti-
microtubule drugs including colchicines, paclitaxel, and vinblas-
tine, in HCT116 cells. The accumulation of phosphorylated
securin was accompanied by higher G2/M arrest and cytotoxicity.
The phosphorylation of securin further leads to its destabilization
and then promotes mitotic exit and mitotic catastrophe of
HCT116 cells. Therefore, we propose that securin is an important
target for the anticancer effects of BPR0L075 in human colorectal
cancer cells.
Mitotic catastrophe could be caused by drugs that target
microtubules or affect the progression of mitosis [8,9]. Many
different cell fates could be caused by mitotic catastrophe. First,
cells can die without mitotic exit. Second, after mitotic exit and
reaching of the G1 phase, cells undergo cell death or senescence
[12]. It has been reported that docetaxel, a microtubule-stabilizing
agent, induces cell death through mitotic catastrophe in human
breast cancer cells [14]. Furthermore, another microtubule-
stabilizing agent, combretastatin-A4 prodrug (CA4P), induces
mitotic catastrophe after mitotic arrest in chronic lymphocytic
leukemia cells [13]. Our results show that BPR0L075 induced
more extensive cell death after drug withdrawal in securin-wild-
type HCT116 cells than in securin-null cells. In addition, recent
study showed that prolonged mitotic arrest induced by anti-
microtubule drugs could lead to more cell death [45]. Moreover,
we found that BPR0L075 treatment for 12 to 24 h induced more
cell death after withdrawing BPR0L075 as compared with
treatment for 4 or 8 h (data not shown). These findings suggest
that BPR0L075 induced mitotic catastrophe through induction of
prolonged mitotic arrest in human colorectal cancer cells.
Nocodazole treatment induces mitotic arrest and phosphoryla-
tion of securin in HCT116 and U2OS cells [46]. Consistently, in
this study we found that BPR0L075 and other anti-microtubule
drugs induced securin phosphorylation in HCT116 cells. It has
been reported that securin is phosphorylated by cdc2 (cdk1) [39].
MAPK kinase also induces securin phosphorylation and regulates
Figure 5. Effects of BPR0L075 withdrawal on cell cycle progression and apoptosis in securin-wild-type and -null HCT116 cells. (A)
Cells were treated with 20 nM BPR0L075 for 12 h and BPR0L075 withdrawal for 12 to 96 h. The cell cycle distribution was determined by flow
cytometry. (B and C) Cells were treated with BPR0L075 for 24 h and BPR0L075 withdrawal or no withdrawal for 24 h. The percentage of dead cells
(Annexin positive and Annexin/PI double positive) were determined by Annexin-V/PI staining. p,0.01(**) indicates a significant difference between
BPR0L075-treated and untreated samples. p,0.01(##) indicates a significant difference between securin-wild-type and -null HCT116 cells.
doi:10.1371/journal.pone.0036006.g005
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cytotoxicity in HCT116 cells. Cells were pretreated with NSC663284, alsterpaullone and purvalanol for 2 h prior to exposure to 20 nM BPR0L075
for 24 h. (A) The levels of securin, phospho-cdc2 (Thr161), phospho-H3 (Ser10) and total cdc2 were analyzed by Western blot. (B) The cell cycle
distribution was determined by flow cytometry. (C) The cell viability was analyzed by MTT assay. p,0.01(**) indicates a significant difference between
alsterpaullone (0.5 mM), Purvalanol (0.5 mM) and BPR075 (20 nM) alone in comparison with control. p,0.01(##) indicates a significant difference
between BPR0L075 alone and pre-treatment with alsterpaullone and purvalanol.
doi:10.1371/journal.pone.0036006.g006
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securin is phosphorylated by DNA-PK (DNA-dependent protein
kinase), which contributes to the blocking of sister chromatin
separation [17,48]. As shown by our results, BPR0L075-induced
phosphorylation of securin was only partially inhibited by cdc2/
CDK specific inhibitor. These results demonstrated that
BPR0L075 induced securin phosphorylation partly through cdc2
activation. Therefore, there might be other kinases that induce
phosphorylation of securin. However, BPR0L075-induced activa-
tion of MAPK kinases was not involved in phosphorylation of
securin. Therefore, we propose that BPR0L075 induces cell death
through the p38 MAPK and JNK pathways, which is independent
of phosphorylation of securin.
Securin has been reported to interact with the DNA repair
protein Ku70. When cells suffer DNA damage, DNA-PK
phosphorylates securin to trigger cell cycle arrest. Then, the
interaction of securin and Ku70 is repressed, thus releasing Ku70
to promote DNA repair [17,48]. In contrast, securin overexpres-
sion may delay mitosis progression and sister chromatid separation
during DNA damage through the inhibition of Ku70 [48]. In our
study, BPR0L075 induced higher G2/M arrest in securin-wild-
type HCT116 cells than in securin-null cells, suggesting that a
greater repair ability and elevated checkpoint activation were
elicited in the presence of securin, which may result from the
phosphorylation and destabilization of securin by BPR0L075.
Expression of securin has been found in various cancers to be
correlated with a poor clinical outcome [49,50]. In this study, we
found that BPR0L075 induced DNA damage and modulated
mitotic regulatory molecules to activate the spindle assembly
checkpoint in HCT116 cells. After BPR0L075 withdrawal, cells of
the G2/M fraction underwent mitotic catastrophe, which was
enhanced by phosphorylation and destabilization of securin.
Moreover, BPR0L075 caused cell death through a caspase-
independent mechanism and activation of JNK and p38 MAPK
pathways (Fig. 8). These findings provided evidence for the first
time that BPR0L075 treatment is beneficial for the treatment of
human colorectal tumors with higher levels of securin. As
BPR0L075 was approved by the U.S. FDA for phase 1 clinical
trial in 2010, the expression levels of securin could be a predictive
factor for deciding the priority of anti-cancer therapy using
BPR0L075 in human cancer cells. Our results also indicate that
targeting securin may be a suitable strategy to broaden the clinical
use of BPR0L075 for various cancers overexpressing securin.
Materials and Methods
Materials
The compound BPR0L075 was synthesized at the Division of
Biotechnology and Pharmaceutical Research, National Health
Research Institutes, Zhuman, Taiwan, ROC. BPR0L075, a white
solid, was obtained in a 72% yield from 6-methoxyindole and
3,4,5-trimethoxybenzoyl chloride and was dissolved in dimethyl
sulfoxide. Propidium iodide (PI; p4170), 3-(4,5-Dimethylthiazol-
2yl)-2,5- diphenyltetrazolium bromide (MTT; M5655), colchicines
Figure 7. Effects of MAPK kinases on BPR0L075-induced phosphorylation of securin and cytotoxicity in HCT116 cells. (A) Cells were
treated with 0 to 80 nM BPR0L075 for 24 h. The levels of phospho-p38, -JNK1/2, and -ERK1/2, and total p38, JNK1/2 and ERK1/2 were determined by
Western blot. (B and C) Cells were pretreated with SB202190, SP600125 and U0126 for 2 h prior to exposure to 20 nM BPR0L075 for 24 h. The levels
of phospho-p38, -JNK1/2, -ERK1/2, -cdc2 (Thr161), and -H3 (Ser10), and total p38, JNK1/2, ERK1/2 and cdc2 were analyzed by Western blot. (D) The cell
viability was determined by MTT assay. (E and F) Cells were pretreated with z-VAD-fmk for 2 h then exposed to 20 nM BPR0L075 for 24 h. The levels
of phospho-p38, -ERK1/2, and -H3 (Ser10), and total p38, ERK1/2 and securin were analyzed by Western blot. The cell viability was analyzed by MTT
assay. p,0.01(**) indicates a significant difference between BPR0L075-treated and untreated samples. p,0.01(##) indicates a significant difference
between BPR0L075 alone and pre-treatment with SB202190 and SP600125.
doi:10.1371/journal.pone.0036006.g007
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Chemical Co. Antibodies specific to ERK(C14), p38a (C-20) and
JNK(C-17) were purchased from Santa Cruz Biotechnology. Anti-
phospho-Histone H2A.X (Ser139) (#05-636) and phospho-
Histone H3 (Ser10) (#05-806) antibodies were purchased from
Upstate. Anti-securin (ab-3305) antibody was purchased from
Abcam. Anti-cdc2 (Ab-1) antibody was purchased from Oncogene
Sciences Products. Anti-actin (MAB1501) antibody was purchased
from Chemicon International. Phospho-cdc2 (Thr161) (#9114),
phospho-chk1 (Ser345) (#2341), phospho-chk2 (Thr68) (#2661),
phospho-SAPK/JNK (Thr183/Tyr185) (#9251), phospho-
ERK1/2 (Thr202/Tyr204) (#9106), phospho-p38 MAP kinase
(Thr180/Tyr182) (#9211), chk1 (#2345), and chk2 (#2662)
antibodies were purchased from Cell Signaling Technology.
Cyclin B1 (Ab-2) and p21 (Ab-1) antibodies, NSC663284
(#217692), alsterpaullone (#126870), MG132 (#474790), cyclo-
heximide (CHX; #2379763), SB202190 (#559388), SP600125
(#420119) and U0126 (#662005) were purchased from Calbio-
chem.
Cell culture
Securin-wild-type and securin-null human HCT116 colorectal
cancer cell lines [27], MCF-7 and MDA-MB-231 human breast
cancer cell lines [51], and MDA-MD-435 human melanoma cell
lines [52] were gifts from Dr. Ji-Hshiung Chen (Department of
Molecular Biology and Human genetics, Tzu Chiu University,
Taiwan). Securin-wild-type and securin-null human HCT116
colorectal cancer cells were routinely maintained in McCoy’5A
medium (Sigma; M4892). MCF-7 and MDA-MB-231 human
breast cancer cells were maintained in Dulbecco’s Modified Eagle
Medium (DMEM; GIBCO; 12800-058). A549 human lung cancer
cell line [53] (gifts from Dr. Lih-Yuan Lin; Department of Life
Science, National Tsing Hua University, Taiwan) were main-
tained in RPMI 1640 medium (GIBCO; 23400-021). The
complete medium was supplemented with 10% fetal bovine serum
(FBS). Unsynchronized cells were used in this study.
Cell viability assay
Cell viability was determined by MTT colorimetric assay.
Briefly, cells were seeded at a density of 5,000–10,000 cells per well
in 96-well plates for 16–24 h. At the end of BPR0L075 treatment,
the cells were washed with phosphate-buffered saline (PBS) and
were re-cultured in culture medium for 2–3 days. Subsequently,
the medium was replaced by new medium supplemented with
0.5 mg/ml of MTT and incubated for 4 h. The viability of the
cells was determined by the measurement of formazan production
converted from MTT, which can be quantified by the develop-
ment of a blue–purple color in DMSO. The intensity of formazan
staining was measured at 545 nm using a plate reader (OPTImax;
Molecular Dynamics), and the relative percentage of viable cells
was calculated by dividing the absorbance resulting from the
treated cells (the average of six wells) by that of the control
included in each experiment.
Cell cycle analysis
The securin-wild-type and -null HCT116 cells were plated at a
density of 500,000 cells per 35-mm culture dish and incubated for
24 h. Cells were treated with BPR0L075 at different concentra-
tions for 24 h. After treatment, cells were trypsinized and fixed
with ice-cold 70% ethanol at 220uC overnight. Fixed cells were
stained with 20 mg/ml PI staining buffer (containing 1% triton X-
100 and 100 mg/ml RNase A) for 30 min. Then, the samples were
analyzed by flow cytometry (FACSCalibur, Becton Dickinson).
DNA histograms were plotted to calculate the percentage of cells
in the different cell cycle phases by ModFit LT software (Vesion
2.0, Becton Dickinson).
Immunoblot analysis
Total cellular protein extracts were prepared according to our
previous study [51]. Equivalent amounts of proteins (20–60 mg/
well) were subjected to electrophoresis using 10–12% sodium
dodecyl sulfate-polyacrylamide gels. After electrophoretic transfer
of proteins onto polyvinlylidine fluoride membranes, the proteins
were sequentially hybridized with a specific primary antibody,
followed by a horseradish peroxidase-conjugated secondary
antibody. The protein bands were visualized on X-ray film using
the ECL detection system (Immobilon
TM Western Chemilumi-
nescent HRP Substrate, WBKLS0500, Milipore), and a gel-
digitizing software, Un-Scan-It gel (Version 5.1; Silk Scientific,
Inc.), was used to quantify the relative intensity of each band on
the X-ray film.
Alkaline phosphatase assay
HCT116 cells untreated and treated with BPR0L075 were
incubated for 24 h. Afterward, samples were washed with PBS,
homogenized using 0.1% Triton X-100, pH 8.0 in PBS for 30 min
at 4uC, and the homogenate was used for the alkaline phosphatase
activity assay kit (BioVision) was used according to the manufac-
turer’s instructions.
Cell death detection
The cell death induced by BPR0L075 was determined by the
analysis of sub-G1 phase cells and Annexin V-PI double staining
assay, for which an Annexin V-PI staining kit (BioVision) was used
according to the manufacturer’s instructions. Cells were analyzed
by flow cytometry (Becton Dickinson), and the percentages of
Figure 8. Proposed model of the anti-cancer effects induced by
BPR0L075 in HCT116 cells. BPR0L075 induced DNA damage, leading
to Chk1/Chk2 activation, inhibition of Cdk1 activity and G2 arrest. It also
modulated Cdk1-dependent phosphorylation of mitotic regulatory
molecules to activate the spindle assembly checkpoint, which was
attenuated in the presence of securin. After BPR0L075 withdrawal, cells
of the G2/M fraction underwent mitotic catastrophe, which was
enhanced by phosphorylation and destabilization of securin. Moreover,
BPR0L075 caused cell death through a caspase-independent mecha-
nism and activation of JNK and p38 MAPK pathways.
doi:10.1371/journal.pone.0036006.g008
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ModFit LT software (Ver. 2.0, Becton-Dickinson).
Statistical analysis
All of the data are represented as the mean 6 standard error of
the mean (SEM) from at least three independent experiments.
Statistical comparisons were performed by one-way analysis of
variance, and further post-hoc testing was conducted using the
statistical software GraphPad Prism 4 (GraphPad Software, Inc.).
A p,0.05 was considered statistically significant.
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